1.MAO Inhibitors in Parkinson's Disease.
Journal of the Korean Neurological Association 1993;11(1):1-7
No abstract available.
Monoamine Oxidase Inhibitors*
;
Monoamine Oxidase*
;
Parkinson Disease*
2.Platelet Monoamine Oxidase in Parkinson Patients:Effect of Deprenyl.
Journal of the Korean Neurological Association 1988;6(2):153-157
No abstract available.
Blood Platelets*
;
Monoamine Oxidase*
;
Selegiline*
3.Platelet monoamine oxidase activity and its relationship to the positive and negative symptoms of schizophrenia.
Sung Hwan YOON ; Young Hoon KIM ; Sung Tae ZIN
Journal of Korean Neuropsychiatric Association 1991;30(1):38-46
No abstract available.
Blood Platelets*
;
Monoamine Oxidase*
;
Schizophrenia*
4.Effect of toloxatone on the pressor effect of tyramine in rat: Comparison with monoamine oxidase inhibition by iproniazid.
Jang Hoon WOO ; Hyung Bae PARK ; Kwang Youn LEE
Journal of Korean Neuropsychiatric Association 1993;32(5):802-809
No abstract available.
Animals
;
Iproniazid*
;
Monoamine Oxidase*
;
Rats*
;
Tyramine*
5.Monoamine oxidase inhibitory effect of Vietnamese plants
Pharmaceutical Journal 2003;0(6):170-173
The vertical HIV transmission from mother to infant can occur in the pregnant period (in utero), during labor or after delivery from breastfeeding. It’s difficult to diagnose HIV-infected newborns by means of serology test, since IgG antibody can infiltrate through placenta from HIV-infected mothers and therefore the serology test is always positive in their babies, even in case the babies were not HIV-infected. In this study, the vertical mother-to-infant HIV-1 transmission in utero was detected by using polymerase chain reaction (PCR) with p17, c2v3 (gp120) and gp41 primers. 37 of 37 (100%) mother blood specimens and 2 of 37 (5.4%) their newborn umbilical cord blood samples were HIV-1 PCR positive. The PCR success rate with P17 and gp41 primers was much higher than that of PCR with c2v3 primer, especially on umbilical cord blood samples. It is recommended that a PCR test using the least 2 primers (p17 and gp41) should be performed at birth to detect HIV-1 seropositive infants and to allow the initiation of antiretroviral therapy. It is necessary to follow up baby health and perform repeatedly HIV-1 PCR on their blood samples to diagnose the timing of HIV-1 transmission.
Plants
;
Monoamine Oxidase Inhibitors
;
Plants, Medicinal
6.Source, metabolism and function of dopamine in digestive tract.
Acta Physiologica Sinica 2020;72(3):336-346
Dopamine (DA), as a catecholamine neurotransmitter widely distributed in the central nervous system and the peripheral tissues, has attracted a lot of attention. Especially in recent years, DA has been found to regulate the function of the immune system, and the involvement of DA in the intestinal mucosal inflammation-related diseases has become a hot research topic. The digestive tract is an important source of peripheral DA, and DA is not only produced in the enteric nervous system and gastrointestinal epithelium, but also produced by intestinal microorganisms. In addition to the synthetases of DA, the DA contents in body tissues are also affected by the two kinds of metabolic enzymes, monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT). This article reviewed the sources, metabolism, and functions of DA in digestive tract, especially focusing on the distribution and function of MAO and COMT, the enzymes degrading DA.
Catechol O-Methyltransferase
;
Catechol O-Methyltransferase Inhibitors
;
Dopamine
;
Gastrointestinal Tract
;
Monoamine Oxidase
;
Monoamine Oxidase Inhibitors
7.Synthesis and monoamine oxidase B inhibitory activities of isoquiritigenin derivatives.
Zhuo KONG ; De-Meng SUN ; Ai-Qian CHEN ; Yun HU
China Journal of Chinese Materia Medica 2019;44(21):4653-4660
Isoquiritigenin,one of the active constituents in the Chinese herb liquorice,is found to have moderate inhibitory activity against rat monoamine oxidase B(MAO-B,IC5047. 2 μmol·L-1). However,the structure-activity relationship(SAR) remains unclear until now. In an attempt to reveal the SAR of inhibition by isoquiritigenin,and to identify more potent and selective inhibitors of MAOB,a series of 13 derivatives based on the scaffold of isoquiritigenin were prepared,and their purities and structures were confirmed by UPLC,1 H-NMR,13 C-NMR and HRMS. These compounds were then evaluated for their ability to inhibit the enzymatic activity of human MAO-B. The SAR of inhibition was summarized and a potent compound C8 with high inhibitory activity(IC501. 4 μmol·L-1) and selectivity(>57 folds over MAO-A) was identified. Enzyme kinetics studies suggested that C8 acted as a competitive inhibitor. In addition,C8 showed little cytotoxicity to glial cells in vitro,which could be a promising lead compound for further study.
Animals
;
Drugs, Chinese Herbal
;
Humans
;
Monoamine Oxidase
;
Monoamine Oxidase Inhibitors
;
Plant Extracts
;
Rats
;
Structure-Activity Relationship
8.An Experimental Study of Microvascular patency Using the Suture Techniques
Kwang Suk LEE ; Tae Seung KIM ; Sei Hyun KIM
The Journal of the Korean Orthopaedic Association 1989;24(4):1245-1250
The suture techniques to anastomose successfully small vassels of 1mm in diameter were continuous suture and interrupted suture, and patency rate of them has been estabilished by orthopaedic surgeon. In 1962, Chase and Schwarz reported better results with interrupted suture than with a continuous suture, Firsching reported less time using with continuous suture than with interrupted suture, but no difference in flow rate, in 1984 Lilly reported that interrupted suture does no result in stenosis of venous end to end anastomoses by continuous suturing technique, Mao reported that there was no statically significant difference between two suture methods in patency rate. The authors have experimentally studied the patency rate and histopathological findings of two suture techniques in the 20 Newzealand white rabbit at the department of Orthopaedic Surgery, Hanyang University Hospital and can be obtained the following results. l. In arterial patency, the interrupted suture and continuous suture were 100% in rate and patency rate in veins were 95% in interrupted suture and 75% in continuous suture. 2. Subintimal hyperplasia occured earlier in arteries than in veins and it may be due to the medial component of vessel. 3. In anastomoses of small vessel the accurate apposition of cut vessels edges decreased the thrombi formation of vessel.
Arteries
;
Constriction, Pathologic
;
Hyperplasia
;
Monoamine Oxidase
;
Suture Techniques
;
Sutures
;
Veins
9.Xanthoangelol and 4-Hydroxyderricin Are the Major Active Principles of the Inhibitory Activities against Monoamine Oxidases on Angelica keiskei K.
Ji Ho KIM ; Yeon Kyung SON ; Gun Hee KIM ; Keum Hee HWANG
Biomolecules & Therapeutics 2013;21(3):234-240
Monoamine oxidase inhibitors (MAOI) have been widely used as antidepressants. Recently, there has been renewed interest in MAO inhibitors. The activity-guided fractionation of extracts from Angelica keiskei Koidzumi (A. keiskei K.) led to the isolation of two prenylated chalcones, xanthoangelol and 4-hydroxyderricin and a flavonoid, cynaroside. These three isolated compounds are the major active ingredients of A. keiskei K. to inhibit the MAOs and DBH activities. Xanthoangelol is a nonselective MAO inhibitor, and a potent dopamine beta-hydroxylase (DBH) inhibitor. IC50 values of xanthoangelol to MAO-A and MAO-B were calculated to be 43.4 microM, and 43.9 microM. These values were very similar to iproniazid, which is a nonselective MAO inhibitor used as a drug against depression. The IC50 values of iproniazid were 37 microM, and 42.5 microM in our parallel examination. Moreover, IC50 value of xanthoangelol to DBH was calculated 0.52 microM. 4-Hydroxyderricin is a potent selective MAO-B inhibitor and also mildly inhibits DBH activity. The IC50 value of 4-hydroxyderricin to MAO-B was calculated to be 3.43 microM and this value was higher than that of deprenyl (0.046 microM) used as a positive control for selective MAO-B inhibitor in our test. Cynaroside is a most potent DBH inhibitor. The IC50 value of cynaroside to DBH was calculated at 0.0410 microM. Results of this study suggest that the two prenylated chalcones, xanthoangelol and 4-hydroxyderricin isolated from A. keiskei K., are expected for potent candidates for development of combined antidepressant drug. A. keiskei K. will be an excellent new bio-functional food material that has the combined antidepressant effect.
Angelica*
;
Antidepressive Agents
;
Chalcones
;
Depression
;
Dopamine beta-Hydroxylase
;
Inhibitory Concentration 50
;
Iproniazid
;
Monoamine Oxidase
;
Monoamine Oxidase Inhibitors
;
Oxidoreductases*
;
Selegiline
10.MAO-inhibitors in Parkinson's Disease.
Experimental Neurobiology 2011;20(1):1-17
Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson's disease (PD). They have been used with or without levodopa (L-DOPA). Non-selective MAO-I due to their side-effect/adverse reaction profile, like tranylcypromine have limited use in the treatment of depression in PD, while selective, reversible MAO-A inhibitors are recommended due to their easier clinical handling. For the treatment of akinesia and motor fluctuations selective irreversible MAO-B inhibitors selegiline and rasagiline are recommended. They are safe and well tolerated at the recommended daily doses. Their main differences are related to (1) metabolism, (2) interaction with CYP-enzymes and (3) quantitative properties at the molecular biological/genetic level. Rasagiline is more potent in clinical practise and has a hypothesis driven more favourable side effect/adverse reaction profile due to its metabolism to aminoindan. Both selegiline and rasagiline have a neuroprotective and neurorestaurative potential. A head-to head clinical trial would be of utmost interest from both the clinical outcome and a hypothesis-driven point of view. Selegiline is available as tablet and melting tablet for PD and as transdermal selegiline for depression, while rasagiline is marketed as tablet for PD. In general, the clinical use of MAO-I nowadays is underestimated. There should be more efforts to evaluate their clinical potency as antidepressants and antidementive drugs in addition to the final proof of their disease-modifying potential. In line with this are recent innovative developments of MAO-I plus inhibition of acetylcholine esterase for Alzheimer's disease as well as combined MAO-I and iron chelation for PD.
Acetylcholine
;
Alzheimer Disease
;
Antidepressive Agents
;
Depression
;
Freezing
;
Handling (Psychology)
;
Head
;
Indans
;
Iron
;
Levodopa
;
Moclobemide
;
Monoamine Oxidase
;
Monoamine Oxidase Inhibitors
;
Parkinson Disease
;
Phenelzine
;
Selegiline
;
Tranylcypromine